PSTVMore cooks in the radiopharma kitchen
Plus Therapeutics is adding SpectronRx to the roster, kicking off manufacturing activities and technology transfer under a pre-existing master services agreement. In plain English: the company is trying to make sure its late-stage clinical supply chain doesn’t rely on one lonely pipe and a prayer.
Why that matters
REYOBIQ and its Rhenium-186 isotope are headed deeper into the GMP pivotal-trial phase, which means manufacturing reliability starts to matter almost as much as the science itself. If you’re an investor, this is the kind of behind-the-scenes news that can look boring until a supply snag turns into a month-long headache.
Building a sturdier backbone
SpectronRx becomes a second GMP manufacturing site alongside Radiomedix, while Telix Pharmaceuticals continues supplying the isotope. That gives Plus a more layered setup:
- a backup manufacturing path,
- more resilience if one vendor stumbles,
- and a cleaner story for scaling later-stage clinical work.
Big picture
This isn’t a flashy revenue headline, but it is the sort of operational plumbing biotech investors obsess over. In radiopharma, the difference between “promising” and “practical” often comes down to whether the company can actually make the stuff at scale without drama.